2′-Ethoxy-5′-Methoxy-2-(5-Methylthienyl)Chalcone Inhibits Collagen-Induced Protein Tyrosine Phosphorylation and Thromboxane Formation during Platelet Aggregation and Adhesion

Lo, Huey‐Ming; Huang, Tur-Fu; Lin, Chun‐Nan; Peng, Hwei-Ling; Wu, Wen‐Bin

doi:10.1159/000235584

Cited by 5 publications

(3 citation statements)

References 26 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Panel notes that the presence of chalcone and coumarin compounds in the NF could have an impact on coagulation, which is in line with observations in the submitted 90‐day study. Chalcones have been shown to inhibit thromboxane formation and exhibit antiplatelet activity (Ko et al., 2004 ; Lin et al., 2001 ; Lo et al., 2009 ). Xanthoangelol, one of the two major chalcones in ashitaba plant, has demonstrated antiplatelet activities in vivo (Ohkura et al., 2016 ).…”

Section: Assessmentmentioning

confidence: 99%

Safety of ashitaba sap as a Novel food pursuant to Regulation (EU) 2015/2283

Turck,

Bohn,

Castenmiller

et al. 2024

EFS2

View full text Add to dashboard Cite

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on ashitaba sap as a novel food (NF) pursuant to Regulation (EU) 2015/2283. Ashitaba sap is collected from harvested stems of Angelica keiskei plants. The principal constituents of the sap with regard to the safety assessment are chalcones (1%-2.25%) and furanocoumarins (< 0.01%). The applicant proposed to use the NF in food supplements at a maximum dose of 780 mg per day. The target population is adults excluding pregnant and lactating women. Taking into consideration the composition of the NF and the proposed uses, the composition of the NF is not nutritionally disadvantageous. There are no concerns regarding genotoxicity of the NF. Based on a 90-day oral toxicity study performed with the product as intended to be placed on the market (30% ashitaba sap powder and 70% cyclodextrins), the Panel establishes a safe dose of 0.5 mg/kg body weight (bw) per day for the product as it is intended to be placed on the market. For the target population, i.e. adults, this safe dose corresponds to 35 mg per day of the product as it is intended to be placed on the market and 137 mg per day of the NF, which is lower than the use level proposed by the applicant. The Panel concludes that the NF is safe for the target population at intake levels up to 137 mg per day.

show abstract

Section: Assessmentmentioning

confidence: 99%

Safety of ashitaba sap as a Novel food pursuant to Regulation (EU) 2015/2283

Turck,

Bohn,

Castenmiller

et al. 2024

EFS2

View full text Add to dashboard Cite

show abstract

“…Their results suggested that AA triggers platelet aggregation by inducing TXB2 activation; however, EMMTC or indomethacin (COX inhibitors) abolished this process. 151 Accordingly, PAF activates the AA metabolic pathway to produce various products, such as PG and TXA2, and the PAF–AA–PG/TXA2 signalling pathway is formed. PG and TXA2 are both AA metabolites, and these derivatives have important regulatory roles in inflammatory responses, glucose metabolism and lipid metabolism, which are associated with the development and progression of many diseases, such as diabetes, hypertension and obesity.…”

Section: Paf-mediated Cytokine Involvement In Nafldmentioning

confidence: 99%

Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease

Yin

Shi

2022

DMSO

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a multifaceted clinicopathological syndrome characterised by excessive hepatic lipid accumulation that causes steatosis, excluding alcoholic factors. Platelet-activating factor (PAF), a biologically active lipid transmitter, induces platelet activation upon binding to the PAF receptor. Recent studies have found that PAF is associated with gamma-glutamyl transferase, which is an indicator of liver disease. Moreover, PAF can stimulate hepatic lipid synthesis and cause hypertriglyceridaemia. Furthermore, the knockdown of the PAF receptor gene in the animal models of NAFLD helped reduce the inflammatory response, improve glucose homeostasis and delay the development of NAFLD. These findings suggest that PAF is associated with NAFLD development. According to reports, patients with NAFLD or animal models have marked platelet activation abnormalities, mainly manifested as enhanced platelet adhesion and aggregation and altered blood rheology. Pharmacological interventions were accompanied by remission of abnormal platelet activation and significant improvement in liver function and lipids in the animal model of NAFLD. These confirm that platelet activation may accompany a critical importance in NAFLD development and progression. However, how PAFs are involved in the NAFLD signalling pathway needs further investigation. In this paper, we review the relevant literature in recent years and discuss the role played by PAF in NAFLD development. It is important to elucidate the pathogenesis of NAFLD and to find effective interventions for treatment.

show abstract

“…These chalcones have demonstrated antioxidant, anti-inflammatory, antiangiogenic, antidiabetic and anti-obesity properties. Furthermore, they have been shown to inhibit platelet aggregation, induce apoptosis in cancer cells and suppress differentiation of preadipocytes to adipocytes [4][5][6][7][8][9][10]. Xanthoangelol, one of the flavenoid chalcones may improve lipid metabolism in the serum and the liver resulting in decreased risk of atherosclerosis and suppression of hepatic lipid accumulation [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Untitled

2017

AOWMC

View full text Add to dashboard Cite

The Japanese plant ashitaba (Angelica keiskei) contains flavenoid chalcones, 4 hydroxyderricin and xanthoangelol has been shown to prevent aspects of metabolic syndrome. A two-part pilot study was undertaken to determine ashitaba's effect on body weight, waist circumference visceral fat in overweight adults. There were two 8 weeks randomized, placebo-controlled, double-blind parallel studies. Part 1: 15 healthy males and Part 2: 26 overweight adults. The treatment groups received 200 mg/day ashitaba chalcone powder (8%) and control groups received a placebo daily. Weight, visceral fat, subcutaneous fat, total fat, BMI, waist circumference and body fat were measured at baseline, weeks 4 and 8. Subjective symptoms, blood tests, urine test, heart rate, blood pressure were conducted to determine safety. There were no significant differences between groups in primary endpoints or safety measures. There was a significant reduction of the visceral fat area and body weight in the treatment group at 8 weeks compared to baseline particularly in those with the highest amount of visceral fat. A decrease in the visceral fat and body weight over 8 weeks was significant only in the treatment group, suggesting future studies are warranted. The study supports the safety of the product.

show abstract

2′-Ethoxy-5′-Methoxy-2-(5-Methylthienyl)Chalcone Inhibits Collagen-Induced Protein Tyrosine Phosphorylation and Thromboxane Formation during Platelet Aggregation and Adhesion

Cited by 5 publications

References 26 publications

Safety of ashitaba sap as a Novel food pursuant to Regulation (EU) 2015/2283

Safety of ashitaba sap as a Novel food pursuant to Regulation (EU) 2015/2283

Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease

Untitled

Contact Info

Product

Resources

About